journal
https://read.qxmd.com/read/22352122/efficacy-and-safety-of-early-versus-late-titration-of-fixed-dose-irbesartan-hydrochlorothiazide-actual-study
#1
RANDOMIZED CONTROLLED TRIAL
Xavier Girerd, David Rosenbaum, Joseph Aoun
Hypertension management guidelines recommend titrating antihypertensive drugs stepwise every 4-6 weeks.We compared efficacy and safety of early versus late titration after 10 weeks' treatment with irbesartan/hydrochlorothiazide. Hypertensive patients uncontrolled on monotherapy were randomized into two groups. In the early titration group (E), patients received irbesartan/hydrochlorothiazide 150/12.5 mg for 2 weeks; uncontrolled patients were up-titrated to 300/25 mg at weeks 2 and 6. In the late titration group (L), patients received 150/12...
December 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/22352121/efficacy-and-safety-of-valsartan-in-hypertensive-taiwanese-patients-post-marketing-surveillance-study
#2
JOURNAL ARTICLE
Chia-Wei Liou, Tung-Chen Yeh, I-Chung Chen, Chi-Hung Huang, Yi-Jen Hung, Kwan-Lih Hsu, Jian-Der Lee, Meng-Huan Lei, Kuan-Cheng Chang, Pei-Yung Liao, Zhih-Cherng Chen, Jackson Wang, Charles Jia-yin Hou
OBJECTIVE: To evaluate the efficacy and safety of valsartan in Taiwanese patients with essential hypertension. METHODS: This 12-week multi-center, open-label, observational, post-marketing surveillance study enrolled 2046 hypertensive patients who were prescribed valsartan 80 or 160 mg as monotherapy or in combination with other antihypertensives based on clinical judgment. The primary endpoint was the incidence rate of dizziness with valsartan 160 mg monotherapy or combination therapy at Week 4...
December 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/22352120/effect-of-fixed-dose-combinations-of-metoprolol-and-amlodipine-in-essential-hypertension-mars-a-randomized-controlled-trial
#3
RANDOMIZED CONTROLLED TRIAL
Padmini Devi, Denis Xavier, Alben Sigamani, Sudhanshu Pandey, Tinku Thomas, Sreenivas Murthy, Kamal Sharma, Balraj Bosco, Ketan Mehta, Sindhu Joshi, Rajeev Gupta, Girija Singh, Jagadish Hiremath, Chadha Ds, Ashokan Nambiar, Prem Pais
AIM: To compare two strengths of a fixed drug combination (FDC) containing metoprolol XL and amlodipine (metoprolol/amlodipine 50/5; and metoprolol/amlodipine 25/2.5) with its components in hypertension. METHODS: We conducted this multicentre, randomized, open-label, trial in Indian patients with hypertension (140-180 mmHg/90-114 mmHg) in 11 centres from nine cities. Eligible patients (n = 402) were randomized into one of five treatment groups (metoprolol XL 50 mg + amlodipine 5 mg, metoprolol XL 25 mg + amlodipine 2...
December 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/22352119/post-registration-studies-for-the-evaluation-of-antihypertensive-drugs
#4
EDITORIAL
Thomas Hedner, Krzysztof Narkiewicz, Sverre Kjeldsen
No abstract text is available yet for this article.
December 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/21247247/effects-of-candesartan-versus-amlodipine-on-home-measured-blood-pressure-qt-dispersion-and-left-ventricular-hypertrophy-in-high-risk-hypertensive-patients
#5
RANDOMIZED CONTROLLED TRIAL
Yasunari Matsuno, Shinya Minatoguchi, Hisayoshi Fujiwara
The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension. We used a prospective, randomized, open-label design with blinded assessment of endpoints. Patients were assigned to candesartan-based therapy up to 12 mg/day (n = 100) or amlodipine-based therapy up to 10 mg/day (n = 101) and followed for 3 years...
April 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/21091270/antihypertensive-efficacy-and-safety-of-olmesartan-and-ramipril-in-elderly-patients-with-mild-to-moderate-systolic-and-diastolic-essential-hypertension
#6
RANDOMIZED CONTROLLED TRIAL
Jean-Michel Mallion, Stefano Omboni, John Barton, Walter Van Mieghem, Krzysztof Narkiewicz, Peter-Klaus Panzer, Juan García Puig, Christodoulos Stefanadis, Robert Zweiker
OBJECTIVE: To compare the efficacy and safety of olmesartan medoxomil (O) and ramipril (R) in elderly patients with essential arterial hypertension. METHODS: After a 2-week placebo washout, 351 elderly hypertensive patients aged 65-89 years (office sitting diastolic blood pressure, DBP, 90-109 mmHg and office sitting systolic blood pressure, SBP, 140-179 mmHg) were randomized double-blind to 12-week treatment with O 10 mg or R 2.5 mg once daily. After the first 2 and 6 weeks, doses could be doubled in non-normalized (blood pressure <140/90 mmHg for non-diabetic and <130/80 mmHg for diabetic) subjects, up to 40 mg for O and 10 mg for R...
April 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/21091269/clevidipine-for-severe-hypertension-in-patients-with-renal-dysfunction-a-velocity-trial-analysis
#7
MULTICENTER STUDY
W Frank Peacock, Joseph Varon, Ramin Ebrahimi, Lala Dunbar, Charles V Pollack
INTRODUCTION: Acute and severe hypertension is common, especially in patients with renal dysfunction (RD). Clevidipine is a rapidly acting (t½∼1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD. The purpose of this analysis was to assess the safety and efficacy of clevidipine in patients with RD. METHODS: VELOCITY, a multicenter open-label study of severe hypertension, enrolled 126 patients with persistent systolic blood pressure (SBP) >180 mmHg...
April 2011: Blood Pressure. Supplement
https://read.qxmd.com/read/20175714/efficacy-and-safety-of-diuretics-in-combination-with-perindopril-in-hypertensive-stroke-patients-results-of-the-japan-perindopril-and-diuretics-on-cerebrovascular-disease-study-j-padoc
#8
MULTICENTER STUDY
Yasuhiro Hasegawa, Kazuyuki Shimada, Takenori Yamaguchi
AIMS: An international randomized controlled trial has shown that anti-hypertensive therapy using perindopril and indapamide significantly reduces the recurrence of stroke. To evaluate the efficacy and safety of diuretics given as add-on therapy to stroke patients, as needed, to perindopril, we conducted a prospective multicenter observational study. METHODS: A total of 3825 hypertensive patients with a history of stroke were enrolled. The patients received a two-step therapy, starting with perindopril alone, and those who failed to achieve the blood pressure target were subsequently given a diuretic...
February 2010: Blood Pressure. Supplement
https://read.qxmd.com/read/20175713/implementation-of-24-hour-blood-pressure-control
#9
EDITORIAL
Thomas Hedner, Sverre Kjeldsen, Krzysztof Narkiewicz
No abstract text is available yet for this article.
February 2010: Blood Pressure. Supplement
https://read.qxmd.com/read/19958075/the-efficacy-and-safety-of-irbesartan-in-primary-hypertension-even-if-a-dose-is-missed-results-from-the-no-problem-study
#10
JOURNAL ARTICLE
Giray Kabakci, Baris Ergun Kaya, Erol Tulumen, Ugur Kocabas, Gulcan Abali, Onur Deveci, Kudret Aytemir, Lale Tokgozoglu, Hilmi Ozkutlu
OBJECTIVES: This study aimed to demonstrate that irbesartan is successful in reducing diastolic blood pressure (BP) even following a missed dose after 6-8-weeks' treatment as measured by 24-hour ambulatory BP monitoring (ABPM). METHODS: Eighty-eight patients (64 females, mean age: 53.4 +/- 10.6 years) with primary hypertension were included in this national, single-center, single-arm, open-label, prospective clinical study. Irbesartan (150 or 300 mg/day) was administered for 8 weeks...
February 2010: Blood Pressure. Supplement
https://read.qxmd.com/read/20050101/validation-of-four-automatic-devices-for-self-measurement-of-blood-pressure-according-to-the-international-protocol-the-pic-indolor-personal-check-comfort-check-my-check-and-travel-check
#11
JOURNAL ARTICLE
Giuseppe Germano, Angelos Psimenos, Francesco Sarullo, Alessandro Venditti, Valerio Pecchioli, Roland Asmar
OBJECTIVE: Four oscillometric devices for self-measurement of blood pressure (SBPM) were evaluated according to the International Protocol of the European Society of Hypertension (ESH) in four separate studies. The Pic Indolor Personal Check, Comfort Check and My Check measure blood pressure (BP) at the brachial level; the Travel Check measures radial BP at the wrist level. METHODS: The International Protocol includes a total number of 33 subjects. In each study and for each subject, four BP measurements were performed simultaneously by two observers using mercury sphygmomanometers alternately with three measurements by the tested device...
October 2009: Blood Pressure. Supplement
https://read.qxmd.com/read/20050100/quality-of-life-and-efficacy-of-nebivolol-in-an-open-label-study-in-hypertensive-patients-the-qolan-study
#12
MULTICENTER STUDY
Michel P Hermans, Olivier De Coster, Laurence Seidel, Adelin Albert, Philippe Van de Borne
BACKGROUND: Nebivolol is a highly selective beta-adrenoreceptor antagonist with vasodilating properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) in real life conditions. In total, 1468 patients were enrolled, 12% diabetics. Nebivolol was prescribed as monotherapy, add-on or switch medication. METHODS: In this open-label, prospective study, the JNC-VII BP target values were used: < 140/90 and < 130/80 mmHg for diabetics...
October 2009: Blood Pressure. Supplement
https://read.qxmd.com/read/20050099/critical-aspects-in-hypertension-diagnosis-and-treatment
#13
EDITORIAL
Thomas Hedner, Krzysztof Narkiewicz, Suzanne Oparil, Sverre Kjeldsen
No abstract text is available yet for this article.
October 2009: Blood Pressure. Supplement
https://read.qxmd.com/read/19205092/combination-of-amlodipine-10-mg-and-valsartan-160-mg-lowers-blood-pressure-in-patients-with-hypertension-not-controlled-by-an-ace-inhibitor-ccb-combination
#14
RANDOMIZED CONTROLLED TRIAL
P Trenkwalder, R Schaetzl, E Borbas, R Handrock, S Klebs
AIMS: This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg. RESULTS: Of 133 patients treated for 5 weeks with ramipril 5 mg and felodipine 5 mg, 105 failed to achieve mean sitting systolic blood pressure <140 mmHg...
December 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/19205091/effectiveness-of-add-on-therapy-with-amlodipine-in-hypertensive-patients-receiving-valsartan
#15
JOURNAL ARTICLE
Derek Weycker, Abdulkadir Keskinaslan, Drew Griffin Levy, John Edelsberg, Alex Kartashov, Gerry Oster
OBJECTIVE: To describe the real-world effectiveness of amlodipine add-on therapy for hypertensive patients receiving valsartan. METHODS: Retrospective cohort study based on USA electronic medical records. The study population included hypertensive patients who, between January 1998 and December 2005, were receiving valsartan and subsequently initiated add-on therapy with amlodipine. Change in systolic blood pressure (SBP)/diastolic blood pressure (DBP), and attainment of goal SBP/DBP (i...
December 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/19203020/efficacy-of-aliskiren-hydrochlorothiazide-single-pill-combinations-in-aliskiren-non-responders
#16
RANDOMIZED CONTROLLED TRIAL
Georg Nickenig, Vladimir Simanenkov, Giuseppe Lembo, Pablo Rodriguez, Thomas Salko, Shannon Ritter, Jack Zhang
OBJECTIVES: To evaluate the efficacy, safety and tolerability of a single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT) in patients with hypertension and an inadequate BP response to aliskiren monotherapy (mean sitting diastolic BP [msDBP] > 90 and < or = 110 mmHg following 4 weeks of aliskiren 300 mg). METHODS: In this study, 880 patients with hypertension and an inadequate BP response to aliskiren monotherapy were randomized to once-daily, double-blind treatment with a single-pill combination of aliskiren/HCT 300/25 mg or 300/12...
December 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/19203019/antihypertensive-efficacy-and-tolerability-of-candesartan-hydrochlorothiazide-32-12-5-mg-and-32-25-mg-in-patients-not-optimally-controlled-with-candesartan-monotherapy
#17
RANDOMIZED CONTROLLED TRIAL
Gerd Bönner
AIM: To evaluate the efficacy and tolerability of candesartan cilexetil 32 mg in combination with hydrochlorothiazide (HCT) 12.5 mg or 25 mg in hypertensive patients not optimally controlled with candesartan monotherapy. PATIENTS AND METHODS: A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks)...
December 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/19203018/more-focus-on-therapeutic-targets-and-improved-tolerability-in-hypertension
#18
EDITORIAL
Thomas Hedner, Sverre E Kjeldsen, Krzysztof Narkiewicz, Susanne Oparil
No abstract text is available yet for this article.
December 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/18705533/the-safety-profile-of-telmisartan-as-monotherapy-or-combined-with-hydrochlorothiazide-a-retrospective-analysis-of-50-studies
#19
RANDOMIZED CONTROLLED TRIAL
Helmut Schumacher, Giuseppe Mancia
BACKGROUND: To compare the tolerability and safety of telmisartan +/- hydrochlorothiazide (HCTZ). METHODS: This retrospective analysis was performed on all hypertensive patients that were enrolled in telmisartan studies. A total of 30 double-blind (n=8023) and 20 open-label (n=8393) studies were available at the time of this analysis, and were included. Treatments investigated were placebo, telmisartan 10-160 mg, or telmisartan 10-160 mg plus HCTZ 6.25-25 mg. The incidence and causality of all adverse events (AEs) and laboratory abnormalities occurring during treatment were recorded...
June 2008: Blood Pressure. Supplement
https://read.qxmd.com/read/18705532/an-eight-week-multicenter-randomized-double-blind-study-to-evaluate-the-efficacy-and-tolerability-of-fixed-dose-amlodipine-benazepril-combination-in-comparison-with-amlodipine-as-first-line-therapy-in-chinese-patients-with-mild-to-moderate-hypertension
#20
RANDOMIZED CONTROLLED TRIAL
Kwo-Chang Ueng, Lung-Chun Lin, Wen-Chol Voon, Ming-Cheng Lin, Yen-Bin Liu, Ho-Ming Su, Po-Yuan Chang, Tsung-Hsien Lin, Wei-Liang Chen, Chau-Chung Wu, Wen-Ter Lai, Chung-Sheng Lin
AIMS: This study sought to compare the antihypertensive efficacy and tolerability of a fixed-dose combination with amlodipine/benazepril with that of amlodipine monotherapy in Chinese hypertensive subjects. RESULTS: This multicenter, double-blind, 8-week study randomized 111 patients to fixed-dose amlodipine besylate/benazepril HCl (2.5/5 mg/day titrated to 5/10 mg/day as needed at week 4 to reach goal blood pressure (BP) <140/90 mmHg) or amlodipine besylate monotherapy (5 mg/day titrated to 10 mg/day as needed)...
June 2008: Blood Pressure. Supplement
journal
journal
31206
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.